BackInsulet Overview

Insulet Operating Income

Insulet's operating income is $510M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$122.10M
37.5% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$507.20M
48.83% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Insulet (PODD) FAQ

Insulet (PODD) currently reports a operating income of $510M as of March 2026. That compares with $340M in the prior-year period — up 48.8% year over year. Use the charts on this page to explore Insulet's operating income history and peer comparisons.

Insulet's operating income increased from $340M to $510M — a 48.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Insulet reported $510M in operating income as of March 2026. That compares with $340M in the prior-year period — up 48.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $510M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Insulet, and consider following PODD for alerts when major investors trade the stock.

Insulet is classified in the Healthcare sector. On operating income, it currently shows $510M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PODD with unrelated industries.